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(56%) patients were men. Annual event rates were 1.7%,
(95% CI 0.4–3.0) for major bleeding, 16.6%, (95% CI
13.0–20.2) for minor bleeding. Mean cost of warfarin
treatment per patient per month was £11.0 (95% CI
10.2–11.6) in patients with no bleeding and £11.9 (95%
CI 10.3–12.5) in patients with minor bleeding (p =
0.095), while in patients with major bleeding the cost was
signiﬁcantly higher (£299.0, 95% CI 74.6–538.9, p =
0.0001). Total cost of warfarin treatment per patient per
year was £159.4 and cost to prevent one stroke per year
was £5260.2. CONCLUSIONS: Warfarin treatment was
cost-effective relative to the costs of stroke. This is likely
to be more cost effective in older people because they have
a higher incidence of stroke.
PCV30
COST-EFFECTIVENESS ANALYSIS OF
ROSUVASTATIN IN GREEK PATIENTS WITH
HYPERLIPIDAEMIA
Papageorgiou M1, Karokis A1, Plumb JM2, Ratcliffe A2,
Southworth H3
1AstraZeneca SA, Athens, Greece; 2AstraZeneca UK Ltd,
Luton, Bedfordshire, United Kingdom; 3AstraZeneca R&D,
Macclesﬁeld, Cheshire, United Kingdom
OBJECTIVES: Rosuvastatin, a new HMG-CoA reductase
inhibitor has been shown to signiﬁcantly reduce LDL cho-
lesterol. The objective to this analysis was to assess the
cost-effectiveness of rosuvastatin compared to all statins
currently available in Greece. METHODS: A cost-
effectiveness model was developed to compare rosuvas-
tatin with atorvastatin, pravastatin, simvastatin and ﬂu-
vastatin over 52-weeks, from the perspective of the Greek
health care system. Effectiveness was deﬁned as the per-
centage of patients reaching European targets and was
derived from a simulation of clinical trials data. Clinical
practice patterns were derived from a survey among lipid
treatment hospital centers. Patients received a 12-week
prescription of the licensed starting dose. If LDL-C
exceeded the target (3.0mmol/L), patients are titrated to
a higher dose of statin every 12 weeks until they achieve
target or the maximum dose is reached. Patients reaching
target (responders), remain at the last prescribed dose,
followed-up every six months. Only direct medical costs
were included. However, Greek patients can freely use
public or private providers, so both public and private
charges were used. Drug cost estimates are based on rosu-
vastatin expected, and on other statins’ current, ex-
factory prices. Budgetary impact estimates were based on
a hypothesized rosuvastatin market share. RESULTS:
More rosuvastatin-treated patients reach target with the
starting dose. Rosuvastatin patients need fewer up-titra-
tion visits and incur lower costs per responder in their
ﬁrst year of treatment compared to atorvastatin, pravas-
tatin, simvastatin and ﬂuvastatin. Rosuvastatin is more
effective and less costly across the available dose ranges.
For a cohort of 10,000 patients, if rosuvastatin where to
have a 25% market share, the model calculates that there
would be 642 additional responders, reducing annual
costs by €728.204,72 and €83.372,08 in private and
public charges respectively. CONCLUSIONS: Rosuvas-
tatin has been demonstrated to be more effective and a
potentially cost-saving therapy for Greek patients.
PCV31
ECONOMIC EVALUATION OF CLOPIDOGREL IN
SECONDARY PREVENTION OF
ATHEROTHROMBOTIC EVENTS IN HUNGARY
Borsos K1, Nagy J2, Belicza E2, Spiesser J3, Gabriel S4,
Blaskó G1
1Sanoﬁ-Synthelabo Hungary, Budapest, Hungary; 2Egészségügy-
kutató Intézet, Budapest, Hungary; 3Sanoﬁ-Synthelabo
Recherche, Bagneux, France; 4Sanoﬁ Synthelabo, Bagneux,
France
OBJECTIVE: To determine the incremental cost-
effectiveness ratio (ICER) of a new antiplatelet agent,
clopidogrel versus no treatment, in secondary prevention
of atherothrombotic events (myocardial infarction,
ischemic stroke, vascular death) in patients for whom
ASA is not a relevant therapeutic strategy in Hungary.
METHODS: A Markov model designed with 7 clinical
states was used to project the ICER as the cost needed to
achieve an extra life year with clopidogrel compared to
no treatment with a time horizon of 2 years. Based on
Fisher’s analysis the model has combined the rates of 
clinical outcomes reported in CAPRIE (clopidogrel arm)
and in the Antiplatelet Trialists’ Collaboration (no treat-
ment arm) with survival data derived from the Framing-
ham database. Costs of atherothrombotic outcomes were
assessed from Hungarian sources. Payer perspective
(Insurer) was used. The ICER was calculated for patients
who could not take ASA (because of intolerance, allergic
or non responders to ASA). A discount rate of 5% was
applied to both costs and beneﬁts. RESULTS: When com-
pared to no treatment 58 events are avoided per 1000
patients treated with clopidogrel which translates into
297 life years gained. The incremental cost is 241,998
HUF (€968). The ICER of clopidogrel versus no treat-
ment is 814 610 HUF (€3256) per life year saved. Sensi-
tivity analyses shows that results are more sensitive to
discount rate and survival data and less sensitive to costs
of atherothrombotic events. CONCLUSION: Clopido-
grel is shown to be extremely cost-effective strategy in
Hungary when ASA is not a relevant alternative.
PCV32
COSTS OF HOSPITALIZATION IN DEPARTMENT
OF CARDIOLOGY FOR PATIENTS WITH
SYSTOLIC HEART FAILURE IN FRANCE
Brunot A1, Lenne X1, Dervaux B1,Vincent C2, Degroote P3
1CRESGE—Université Catholique de Lille, Lille, France; 2Orion
Pharma France, Levallois Perret, France; 3Centre Hospito-
Universitaire de Lille, Lille, France
655Abstracts
OBJECTIVES: To measure cost of care in cardiologic
departements for inpatients with decompensated, systolic
heart failure and to study major cost drivers. METHODS:
In 2000, a multicentric observational study was set up
within 8 cardiology departments in France. Patients over
18, hospitalized with decompensated systolic heart failure
(HF), and LVEF < 45% were prospectively included. Data
were collected up to ﬁnal discharge from the department.
Cost of lab tests, procedures, blood products and phar-
macy were extracted from ofﬁcial guidelines or public
hospital sources. Other patients’ stay ﬁxed costs, includ-
ing staff and overheads, were averaged from hospital
sources. Factorial analysis was performed on patients’
socio-demographic and clinical caracteristics. RESULTS:
Two hundred twenty-one patients were included, with
mean age 66 years, 62% male. Main diagnoses were coro-
nary heart disease (CHD): 48%, and dilated cardiomy-
opathy: 28%. Average length of stay (LOS) in cardiologic
departement was 12.4 days. Average total cost was €5770
(sd: €3975) for each patient. Factors linked to higher costs
were: transfert from an other department, emergency
admittance, new diagnosis, no previous treatment, and
ﬁrst hospitalization. Factorial analysis identiﬁed 3 clus-
ters: one cluster of elderly patients, mean age 77 years,
higher LVEF (36%), 60% previously known HF, two
clusters with younger patients: mean age 64 years, mainly
with CHD; patients in cluster 2 had 97% HF already
known and 88% former hospitalization, lower LVEF
(26%), whereas in cluster3 100% new diagnosis of HF,
high proportion of ICU stay. Hospitalization costs were
higher (p < 0.01) in cluster 3 (€6792) than in cluster 2
(€5692) or 1 (€5016), without difference in LOS. Main
cost difference was linked to invasive cardio-vascular pro-
cedures (€1177 in cluster 3, versus €266 in other clusters,
p < 0.001). CONCLUSION: Higher costs for patients
with decompensated heart failure were related to ﬁrst
hospitalization and new diagnosis, intensive cardiac pro-
cedures, mainly for coronary artery disease. Hospitaliza-
tion costs were lower for relapses.
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OBJECTIVE: To generate estimates of the cost-
effectiveness of combined ACE-inhibitor and calcium
antagonist therapy (Tarka) versus ACE-inhibitors (usual
care) in patients with heart failure after myocardial
infarction in the US health care setting. METHODS:
Markov process analysis techniques were used to model
the health eonomic outcomes. Data on probabilities of
clinical events were derived from clinical trial data and
other published literature; units of health care utilization
were derived from the literature and the HCUP database;
prices/tariffs were derived from ofﬁcial lists. Study per-
spective was that of the third party payer. RESULTS: An
analysis over the Tarka trial period shows that Tarka
decreases the costs from US$24,567 to US$19,907. The
mortality for Tarka is at least equal to usual care (1.96%
versus 2.04%) and consequently Tarka can be considered
dominant over usual care. Tarka remains cost saving over
a follow-up of 5 and 10 years. The cost saving are respec-
tively US$5120 and US$3642. The use of Tarka also leads
to substantial reductions in cumulative mortality, which
are respectively 9.4% and 11.7% over 5 and 10 years.
The lifetime model shows that the use of Tarka leads to
an incremental cost-effectiveness ratio of US$1730 per
life year gained. Probabilistic sensitivity analysis showed
that the probability is 55% that the incremental cost
effectiveness ratio of Tarka is less than US$5000 per life
year gained, while the incremental cost effectiveness ratio
will always be less than US$10,000. CONCLUSION: The
results showed that the favourable clinical beneﬁt of
Tarka results in positive short and long-term health eco-
nomic beneﬁts.
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OBJECTIVE: Pressure-based fractional ﬂow reserve
(FFR) is an invasive test for assessing the functional 
signiﬁcance of intermediate coronary stenoses. Previous
studies have found that FFR testing to guide percutaneous
coronary intervention (PCI) is cost-effective. In this study
we evaluate the impact of using drug-eluting stents (DES)
on this decision. METHODS: We developed a Markov
model to compare the long-term costs and outcomes of 2
strategies for patients with indeterminate coronary steno-
sis scheduled for PCI: 1) Universal PCI (UNIV) without
FFR testing, and 2) FFR testing followed by PCI only for
those with FFR < 0.75 (TEST). Base-case: 60-year-old
man under the optimistic assumption (for UNIV) that 
relative mortality reduction with revascularization is
independent of functional signiﬁcance. Data: long-term
clinical outcomes of PCI and medical management includ-
ing recurrence rates, disease progression, and quality of
life based on published literature. Based on ﬁxed effects
meta-analysis, we estimated that DES reduce clinical
restenosis rates by 79% compared with bare metal stents
(BMS). Perspective: societal. Discounting: 3% per year.
RESULTS: For the case of BMS, UNIV increased costs by
$2800/patient and improved outcome by 12 quality-
adjusted life days (QALD), yielding an incremental cost-
